Team:UCSF

From 2010.igem.org

(Difference between revisions)
(Project Description)
 
(113 intermediate revisions not shown)
Line 1: Line 1:
-
{{UCSF/Head}}
+
<html>
 +
<script>
 +
var Numbering="N1";
 +
</script>
 +
</html>
 +
{{Template:UCSF/BannerAndNav}}
 +
{{Template:UCSF/LeftStart}}
 +
<br>
 +
===Project Description===
-
{{UCSF/Jixedbar}}
+
Killer cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response.
 +
Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
-
 
+
<br>
-
[[Image:UCSFban.JPG|905px|center|UCSF iGEM Banner]]
+
-
 
+
-
{| style="color:white;background-color:#FFA35B;" cellpadding="3" cellspacing="2" border="0" bordercolor="#fff" width="94%" align="center"
+
-
!align="center"|[[Team:UCSF|Home]]
+
-
!align="center"|[[Team:UCSF/Team|Team]]
+
-
!align="center"|[https://igem.org/Team.cgi?year=2010&team_name=UCSF Official Team Profile]
+
-
!align="center"|[[Team:UCSF/Project|Project]]
+
-
!align="center"|[[Team:UCSF/Parts|Parts Submitted to the Registry]]
+
-
!align="center"|[[Team:UCSF/Modeling|Modeling]]
+
-
!align="center"|[[Team:UCSF/Notebook|Notebook]]
+
-
!align="center"|[[Team:UCSF/Safety|Safety]]
+
-
|}
+
<html>
<html>
-
<br>
+
<a href="https://2010.igem.org/Team:UCSF/Project/Precision"><img src="https://static.igem.org/mediawiki/2010/2/28/UCSF_precision_home_icon.png" width="208" border="0" alt="Greater Precision" />
-
<div style="text-align:center;  font-size: large; color: #0099CC"><b> Work In Progress </b></div>
+
</a>
-
<br>
+
<a href="https://2010.igem.org/Team:UCSF/Project/Signaling"><img src="https://static.igem.org/mediawiki/2010/9/9a/UCSF_signaling_home_icon.png" width="208" border="0" alt="Stronger Signaling" />
-
<br>
+
</a>
 +
<a href="https://2010.igem.org/Team:UCSF/Project/Arsenal" ><img src="https://static.igem.org/mediawiki/2010/3/35/UCSF_arsenal_home_icon.png" border="0" width="208" alt="Better Arsenal" />
 +
</a>
 +
<br><br>
 +
 
</html>
</html>
 +
{{Template:UCSF/LeftEnd}}
 +
{{Template:UCSF/RightStart}}
 +
<html>
 +
<br><br>
 +
<h3 style="color:black;">TEAM</h3>
 +
<div align="center">
 +
<a href="https://2010.igem.org/Team:UCSF/Team"><img src="https://static.igem.org/mediawiki/2010/f/ff/Team_photo.png" /></a>
 +
</div>
 +
<br><br>
-
=='''Project Description'''==
+
<h3 style="color:black;">SPONSORS</h3>
 +
<div align="center">
 +
<a href="https://2010.igem.org/Team:UCSF/Sponsors"><img src="https://static.igem.org/mediawiki/2010/3/38/Sponsors_2010.png" width="200px" /></a>
 +
</div>
-
Natural killer (NK) cells of the immune system identify cancer and virally-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, NK cells use a variety of receptors, which bind to specific ligands at the target cells’ surface. The balance between activating and inhibitory signals will tell the NK cell if the target cell is diseased or healthy, respectively. If the target cell is deemed potentially dangerous, the NK cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the NK cell releases cytotoxic granules to kill the target cell without harming any nearby cells allowing for a direct, apoptotic death.
+
<br><br>
-
 
+
<h5 style="color:black;">Follow us on <a href="http://twitter.com/#!/iGEM_UCSF">Twitter!</a></h5>
-
Our team will focus on improving NK cells’ specificity and killing efficiency towards certain cancer types. By using synthetic biology tools and logic gates’ design, we hope to create powerful killing biomachines for the fight against cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.
+
-
<html>
+
-
<script type="text/javascript">
+
-
function getEdit(){
+
-
var PageURL = document.URL;
+
-
var RightURL = PageURL.substr(21);
+
-
location.href="wiki/index.php?title="+RightURL+"&amp;action=edit";
+
-
}
+
-
</script>
+
-
<li><a onClick=RightURL><span>M</span></a></li>
+
-
<li><a onClick="javascript:getEdit()"><span>P</span></a></li>
+
</html>
</html>
-
=='''Project'''==
 
 +
 +
{{Template:UCSF/RightEnd}}
__NOTOC__
__NOTOC__

Latest revision as of 22:27, 15 November 2010


Project Description

Killer cells of the immune system identify cancer and pathogen-infected cells and kill them. These potent killers travel throughout the body, recognizing proteins and other molecules on the surface of cells. In order to differentiate between healthy and diseased cells, killer cells use a variety of receptors, which bind to specific ligands on the target cells’ surface. If the target cell is deemed potentially dangerous, the killer cell grips the target cell tightly and creates an immunological synapse at the site of adhesion. Within this immunological synapse, the killer cell releases cytotoxic granules to kill the target cell without harming nearby cells, triggering a directed apoptotic response.

Our team will focus on improving killer cells’ specificity and killing efficiency towards cancerous target cells. By using tools of synthetic biology, we hope to create powerful killing bio-machines to fight cancer. Our newly engineered synthetic devices would have the potential to enhance current adoptive cell-based immunotherapy for cancer patients.


Greater Precision Stronger Signaling Better Arsenal